Advertisement

Bijblijven

, Volume 34, Issue 2, pp 167–178 | Cite as

Biologicals en vaccinatie

  • Albert Vollaard
Article
  • 40 Downloads

Samenvatting

Patiënten die immunosuppressiva gebruiken hebben een verhoogd risico op infecties en vaak ook op een ernstiger beloop van ziekte. Vaccinatie kan dat risico verminderen, maar immunosuppressiva verminderen ook de vaccinatierespons. Zowel de kwantitatieve respons – de hoogte van antistofconcentraties en aantallen geactiveerde afweercellen en T‑ en B‑geheugencellen – als de kwalitatieve respons – hoe goed een antistof of afweercel een interactie aangaat met een antigeen van een ziekmakend micro-organisme – kan afnemen. Daardoor ontstaat er na vaccinatie soms slechts suboptimale bescherming of is de duur van de bescherming verkort. De verschillende soorten immunosuppressiva verschillen in hun effect op de vaccinatierespons. In deze bijdrage wordt specifiek ingegaan op de vaccinatierespons tijdens het gebruik van biologicals, zoals die bij auto-immuunaandoeningen worden gebruikt. Effectiviteit en veiligheid van de verschillende soorten vaccins, vooral van het influenza-, pneumokokken- en zostervaccin, worden besproken bij het gebruik van anti-TNF en anti-CD20- (rituximab) medicatie. Er wordt verduidelijkt dat tijdens gebruik van anti-TNF-medicatie de vaccinatierespons minder onderdrukt wordt dan tijdens gebruik van anti-CD20-therapie.

Literatuur

  1. 1.
    Riedel S. Edward Jenner and the history of smallpox and vaccination. Proc (Bayl Univ Med Cent). 2005;18(1):21–5.CrossRefGoogle Scholar
  2. 2.
    Houweling H, Verweij M, Ruitenberg EJ. Criteria for inclusion of vaccinations in public programmes. Vaccine. 2010;28(17):2924–31.CrossRefPubMedGoogle Scholar
  3. 3.
    Stuck AE, Minder CE, Frey FJ. Risk of infectious complications in patients taking glucocorticosteroids. Rev Infect Dis. 1989;11(6):954–63.CrossRefPubMedGoogle Scholar
  4. 4.
    Kinsey BM, Jackson DC, Orson FM. Anti-drug vaccines to treat substance abuse. Immunol Cell Biol. 2009;87(4):309–14.CrossRefPubMedGoogle Scholar
  5. 5.
    Joniau S, Abrahamsson PA, Bellmunt J, Figdor C, Hamdy F, Verhagen P, et al. Current vaccination strategies for prostate cancer. Eur Urol. 2012;61(2):290–306.CrossRefPubMedGoogle Scholar
  6. 6.
    Lohmueller J, Finn OJ. Current modalities in cancer immunotherapy: immunomodulatory antibodies, CARs and vaccines. Pharmacol Ther. 2017;178:31–47.CrossRefPubMedGoogle Scholar
  7. 7.
    Cooksley CD, Avritscher EB, Bekele BN, Rolston KV, Geraci JM, Elting LS. Epidemiology and outcomes of serious influenza-related infections in the cancer population. Cancer. 2005;104(3):618–28.CrossRefPubMedGoogle Scholar
  8. 8.
    Vollaard A, Schreuder I, Slok-Raijmakers L, Opstelten W, Rimmelzwaan G, Gelderblom H. Influenza vaccination in adult patients with solid tumours treated with chemotherapy. Eur J Cancer. 2017;76:134–43.CrossRefPubMedGoogle Scholar
  9. 9.
    Kramer JM, LaRussa P, Tsai WC, Carney P, Leber SM, Gahagan S, et al. Disseminated vaccine strain varicella as the acquired immunodeficiency syndrome-defining illness in a previously undiagnosed child. Pediatrics. 2001;108(2):E39.CrossRefPubMedGoogle Scholar
  10. 10.
    Cheent K, Nolan J, Shariq S, Kiho L, Pal A, Case Report AJ. Fatal case of disseminated BCG infection in an infant born to a mother taking infliximab for Crohn’s disease. J Crohns Colitis. 2010;4(5):603–5.CrossRefPubMedGoogle Scholar
  11. 11.
    Plotkin SA. Correlates of protection induced by vaccination. Clin Vaccine Immunol. 2010;17(7):1055–65.CrossRefPubMedCentralPubMedGoogle Scholar
  12. 12.
    McMahan ZH, Bingham CO 3rd. Effects of biological and non-biological immunomodulatory therapies on the immunogenicity of vaccines in patients with rheumatic diseases. Arthritis Res Ther. 2014;16(6):506.CrossRefPubMedCentralPubMedGoogle Scholar
  13. 13.
    Visser LG. The immunosuppressed traveler. Infect Dis Clin North Am. 2012;26(3):609–24.CrossRefPubMedGoogle Scholar
  14. 14.
    Buhler S, Eperon G, Ribi C, Kyburz D, Gompel F van, Visser LG, et al. Vaccination recommendations for adult patients with autoimmune inflammatory rheumatic diseases. Swiss Med Wkly. 2015;145:w14159.PubMedGoogle Scholar
  15. 15.
    Kapetanovic MC, Roseman C, Jonsson G, Truedsson L, Saxne T, Geborek P. Antibody response is reduced following vaccination with 7‑valent conjugate pneumococcal vaccine in adult methotrexate-treated patients with established arthritis, but not those treated with tumor necrosis factor inhibitors. Arthritis Rheum. 2011;63(12):3723–32.CrossRefPubMedGoogle Scholar
  16. 16.
    Gelinck LB, Teng YK, Rimmelzwaan GF, Bemt BJ van den, Kroon FP, Laar JM van. Poor serological responses upon influenza vaccination in patients with rheumatoid arthritis treated with rituximab. Ann Rheum Dis. 2007;66(10):1402–3.CrossRefPubMedCentralPubMedGoogle Scholar
  17. 17.
    Assen S van, Elkayam O, Agmon-Levin N, Cervera R, Doran MF, Dougados M, et al. Vaccination in adult patients with auto-immune inflammatory rheumatic diseases: a systematic literature review for the European League Against Rheumatism evidence-based recommendations for vaccination in adult patients with auto-immune inflammatory rheumatic diseases. Autoimmun Rev. 2011;10(6):341–52.CrossRefPubMedGoogle Scholar
  18. 18.
    Rahier JF, Moutschen M, Gompel A van, Ranst M van, Louis E, Segaert S, et al. Vaccinations in patients with immune-mediated inflammatory diseases. Rheumatology (Oxford). 2010;49(10):1815–27.CrossRefGoogle Scholar
  19. 19.
    Shea KM, Edelsberg J, Weycker D, Farkouh RA, Strutton DR, Pelton SI. Rates of pneumococcal disease in adults with chronic medical conditions. Open Forum Infect Dis. 2014;1(1):ofu24.CrossRefPubMedCentralPubMedGoogle Scholar
  20. 20.
    Blumentals WA, Arreglado A, Napalkov P, Toovey S. Rheumatoid arthritis and the incidence of influenza and influenza-related complications: a retrospective cohort study. BMC Musculoskelet Disord. 2012;13:158.CrossRefPubMedCentralPubMedGoogle Scholar
  21. 21.
    Tam LS, Chan PK, Ho SC, Yu MM, Yim SF, Cheung TH, et al. Natural history of cervical papilloma virus infection in systemic lupus erythematosus – a prospective cohort study. J Rheumatol. 2010;37(2):330–40.CrossRefPubMedGoogle Scholar
  22. 22.
    Govaert TM, Thijs CT, Masurel N, Sprenger MJ, Dinant GJ, Knottnerus JA. The efficacy of influenza vaccination in elderly individuals. A randomized double-blind placebo-controlled trial. JAMA. 1994;272(21):1661–5.CrossRefPubMedGoogle Scholar
  23. 23.
    Tseng HF, Harpaz R, Luo Y, Hales CM, Sy LS, Tartof SY, et al. Declining effectiveness of Herpes Zoster vaccine in adults aged ≥ 60 years. J Infect Dis. 2016;213(12):1872–5.CrossRefPubMedGoogle Scholar
  24. 24.
    Romero-Steiner S, Musher DM, Cetron MS, Pais LB, Groover JE, Fiore AE, et al. Reduction in functional antibody activity against streptococcus pneumoniae in vaccinated elderly individuals highly correlates with decreased IgG antibody avidity. Clin Infect Dis. 1999;29(2):281–8.CrossRefPubMedGoogle Scholar
  25. 25.
    Jain S, Self WH, Wunderink RG. Community-acquired pneumonia requiring hospitalization. N Engl J Med. 2015;373(24):2382.PubMedGoogle Scholar

Copyright information

© Bohn Stafleu van Loghum is een imprint van Springer Media B.V., onderdeel van Springer Nature 2018

Authors and Affiliations

  1. 1.RIVM Landelijke Coördinatie Infectieziektebestrijding (LCI)BilthovenNederland

Personalised recommendations